SCHEDULE 13G/A: Janus Henderson Group PLC Discloses 7.3% Passive Stake in IDEAYA Biosciences, Inc.
Beneficial Ownership Report
Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 7.3% beneficial ownership stake in IDEAYA Biosciences, Inc. as of March 31, 2025, held for passive investment purposes.
Summary
- Janus Henderson Group PLC, a Jersey-based parent holding company and investment adviser, has filed an Amendment No. 3 to Schedule 13G regarding its beneficial ownership in IDEAYA Biosciences, Inc.
- As of March 31, 2025, Janus Henderson Group PLC beneficially owned 6,402,537 shares of IDEAYA Biosciences, Inc. Common Stock.
- This ownership represents 7.3% of the total class of securities.
- The filing indicates that the securities are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer, consistent with a passive investment strategy.
- Indirect subsidiaries, including JHIUS, JHIUKL, and JHIAIFML, are registered investment advisers furnishing investment advice to Managed Portfolios, with JHIUS specifically deemed to be the beneficial owner of 6,304,484 shares, representing 7.2% of the class.
Sentiment
Score: 5
Explanation: Neutral. This is a routine regulatory filing disclosing beneficial ownership, not an announcement of company performance or strategic changes. It reflects a passive investment position.
Future Outlook
NA
Industry Context
Schedule 13G filings are standard regulatory disclosures in the financial industry, indicating that an institutional investor has acquired a significant passive ownership stake (over 5%) in a publicly traded company. For the biotechnology sector, such filings demonstrate institutional confidence and can signal long-term investment interest in the company's potential, without implying an intent to influence management or control.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can be viewed positively as a vote of confidence from a major asset manager, potentially enhancing market perception of the stock's stability.
Key Dates
| Date | Description |
|---|---|
| 2022-12-09 | Date the Power of Attorney was executed by Janus Henderson Group plc, authorizing individuals to sign SEC filings. |
| 2025-03-31 | Date of the event which requires the filing of this statement, representing the snapshot of beneficial ownership. |
| 2025-05-14 | Date the Schedule 13G Amendment No. 3 was signed and filed with the SEC. |
Keywords
IDEAYA Biosciences, Janus Henderson Group, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Biotechnology, SEC Filing, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.